Latest news

Immutep Limited (ASX: IMM; NASDAQ: IMMP) is pleased to announce it has received a €1,804,341 (~ A$2,693,046 ) research and development (R&D) tax incentive payment in cash from the French Government under its Crédit d'Impôt Recherche scheme (CIR).

Immutep Limited (ASX: IMM; NASDAQ: IMMP) provides a clinical development update for its first-in-class LAG-3 antigenpresenting cell (APC) activator product candidate, eftilagimod alpha ("efti").

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce the grant of a new patent (number7074341) entitled "Anti- LAG-3 Antibodies" by the Japanese Patent Office.

– Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, today reports new biomarker and exploratory analysis data from its Phase IIb AIPAC trial. The data was presented at ESMO's Breast Cancer Congress in a poster presentation which is available